Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer

Oyama, Nobuyuki; Akino, Hironobu; Suzuki, Yuji; Kanamaru, Hiroshi; Miwa, Yoshiji; Tsuka, Harutoshi; Sadato, Norihiro; Yonekura, Yoshiharu; Okada, Kenichiro

doi:10.1016/s1095-0397(01)00065-6

Cited by 102 publications

(63 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Target cells (C4-2 and DU 145) were freshly harvested from tissue culture flasks, and a single-cell suspension was prepared in phosphate-buffered saline (PBS) with 3% fetal calf serum and 0.1% NaN 3 . Approximately 10 5 cells were incubated with 50 mL of primary mAb 3/A12 at concentrations between 0.15 and 2,600 nM for 1 h on ice.…”

Section: Flow Cytometrymentioning

confidence: 99%

PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen

Elsässer‐Beile¹,

Reischl²,

Wiehr³

et al. 2009

J Nucl Med

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, is highly expressed by virtually all prostate cancers and is currently the focus of several diagnostic and therapeutic strategies. We have previously reported on the generation of several monoclonal antibodies (mAb) and antibody fragments that recognize and bind with high affinity to the extracellular domain of cell-adherent PSMA. This article reports the in vivo behavior and tumor uptake of the radiolabeled anti-PSMA mAb 3/A12 and its potential as a tracer for PET. Methods: The mAb 3/A12 was conjugated with the chelating agent 1,4,7,10-tetraazacyclododecane-N,N9,N$,N9$-tetraacetic acid (DOTA) and radiolabeled with 64 Cu. Severe combined immunodeficient mice bearing PSMA-positive C4-2 prostate carcinoma xenografts were used for small-animal PET imaging. Mice with PSMA-negative DU 145 tumors served as controls. For PET studies, each animal received 20-30 mg of radiolabeled mAb corresponding to an activity of 7.6-11.5 MBq. Imaging was performed 3, 24, and 48 h after injection. After the last scan, the mice were sacrificed and tracer in vivo biodistribution was measured by g-counting. Results: Binding of the mAb 3/A12 on PSMA-expressing C4-2 cells was only minimally influenced by DOTA conjugation. The labeling efficiency using 64 Cu and DOTA-3/A12 was 95.3% 6 0.3%. The specific activity after 64 Cu labeling was between 327 and 567 MBq/mg. After tracer injection, static small-animal PET images of mice with PSMA-positive tumors revealed a tumor-to-background ratio of 3.3 6 1.3 at 3 h, 7.8 6 1.4 at 24 h, and 9.6 6 2.7 at 48 h. In contrast, no significant tracer uptake occurred in the PSMA-negative DU 145 tumors. These results were confirmed by direct counting of tissues after the final imaging. Conclusion: Because of the high and specific uptake of 64 Cu-labeled mAb 3/A12 in PSMA-positive tumors, this ligand represents an excellent candidate for prostate cancer imaging and potentially for radioimmunotherapy.

show abstract

Section: Flow Cytometrymentioning

confidence: 99%

PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen

Elsässer‐Beile¹,

Reischl²,

Wiehr³

et al. 2009

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…18 F-FDG PET imaging has been shown to prognosticate survival in various tumor entities (11,12). Especially in tumors with variable 18 F-FDG uptake, such as hepatocellular carcinoma (13,14), prostate cancer (15,16), and gastrointestinal stroma tumors (17,18), a correlation between 18 F-FDG avidity and biologic behavior of the tumor (indicated by patient survival) has been shown to facilitate outcome prediction or metabolic grading by noninvasive measures. Recent studies have also shown such value for NENs (19,20).…”

mentioning

confidence: 99%

Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸F-FDG PET: Feasibility of a Metabolic Grading System

et al. 2014

View full text Add to dashboard Cite

The tumor proliferation marker, Ki-67 index, is a well-established prognostic marker in gastroenteropancreatic neuroendocrine neoplasms (NENs). Noninvasive molecular imaging allows whole-body metabolic characterization of metastatic disease. We investigated the prognostic impact of 18 F-FDG PET in inoperable multifocal disease. Methods: Retrospective, dual-center analysis was performed on 89 patients with histologically confirmed, inoperable metastatic gastroenteropancreatic NENs undergoing 18 F-FDG PET/CT within the staging routine. Metabolic (PET-based) grading was in accordance with the most prominent 18 F-FDG uptake (reference tumor lesion): mG1, tumor-to-liver ratio of maximum standardized uptake value # 1.0; mG2, 1.0-2.3; mG3, .2.3. Other potential variables influencing overall survival, including age, tumor origin, performance status, tumor burden, plasma chromogranin A ($600 μg/L), neuronspecific enolase ($25 μg/L), and classic grading (Ki-67-based) underwent univariate (log-rank test) and multivariate analysis (Cox proportional hazards model), with a P value of less than 0.05 considered significant. Results: The median follow-up period was 38 mo (95% confidence interval [CI], 27-49 mo); median overall survival of the 89 patients left for multivariate analysis was 29 mo (95% CI, 21-37 mo). According to metabolic grading, 9 patients (10.2%) had mG1 tumors, 22 (25.0%) mG2, and 57 (64.8%) mG3. On multivariate analysis, markedly elevated plasma neuron-specific enolase (P 5 0.016; hazard ratio, 2.9; 95% CI, 1.2-7.0) and high metabolic grade (P 5 0.015; hazard ratio, 4.7; 95% CI, 1.2-7.0) were independent predictors of survival. Conclusion: This study demonstrated the feasibility of prognostic 3-grade stratification of metastatic gastroenteropancreatic NENs by whole-body molecular imaging using 18 F-FDG PET.

show abstract

“…and 18 F-FDG, being a marker of glucose metabolism, is not highly effective in delineating it from surrounding tissue (4). Although 18 F-FDG has been shown to be effective in the assessment of high-grade primary tumors and metastatic disease (5)(6)(7)(8)(9), other obstacles still leave much to be desired for its use with prostate malignancies, especially at early stages. The bladder clearance of 18 F-FDG also poses an obstacle as it is in the same anatomic region as the prostate, and, therefore, the primary tumor.…”

mentioning

confidence: 99%

1-¹¹C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer

Vāvere¹,

Kridel²,

Wheeler³

et al. 2008

J Nucl Med

158

122

View full text Add to dashboard Cite

Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer

Cited by 102 publications

References 11 publications

PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen

PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen

Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸F-FDG PET: Feasibility of a Metabolic Grading System

1-¹¹C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer

Contact Info

Product

Resources

About

Prognostic Value of 2-Deoxy-2-[F-18]Fluoro-D-Glucose Positron Emission Tomography Imaging for Patients with Prostate Cancer

Cited by 102 publications

References 11 publications

PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen

PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen

Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by 18F-FDG PET: Feasibility of a Metabolic Grading System

1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer

Contact Info

Product

Resources

About

Prognostic Stratification of Metastatic Gastroenteropancreatic Neuroendocrine Neoplasms by ¹⁸F-FDG PET: Feasibility of a Metabolic Grading System

1-¹¹C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer